Bambusa Therapeutics reports preliminary positive results for BBT001 in atopic dermatitis

Bambusa Therapeutics has released preliminary results from a Phase 1 clinical trial for its drug candidate BBT001, indicating significant efficacy and a favorable safety profile in patients with moderate-to-severe atopic dermatitis. The data suggests rapid symptom relief and a potential for infrequent dosing.

The proof-of-concept study involved 17 patients randomized to receive either BBT001 or placebo over four weeks. Patients treated with BBT001 showed statistically significant improvements in Eczema Area and Severity Index (EASI) scores starting at week one. Rapid itch relief was also observed as early as Day 1 following the initial dose.

BBT001 is a half-life extended bispecific antibody targeting the IL-4Rα and IL-31 pathways. The preliminary findings also demonstrated robust and sustained suppression of Type 2 inflammatory biomarkers. The drug candidate was well-tolerated, with no serious adverse events reported. Furthermore, an extended half-life was observed, supporting the potential for maintenance dosing as infrequently as every three months.

Bambusa Therapeutics expects to release additional topline data from its ongoing BBT001 studies in atopic dermatitis and chronic spontaneous urticaria in the first half of 2027. The company is focused on developing next-generation, long-acting bispecific antibodies for immunology and inflammation indications.